deltatrials
Recruiting INTERVENTIONAL NCT07545811

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 Open-Label, Multicenter Study of JANX014 in Participants With Prostate Cancer

Sponsor: Janux Therapeutics

Conditions Castration-resistant Prostate Cancer Metastatic Castration-resistant Prostate Cancer Prostate Cancer
Interventions JANX014
Updated 1 time since 2026 Last updated: Apr 16, 2026 Started: Apr 15, 2026 Primary completion: May 1, 2028 Completion: Mar 1, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Castration-resistant Prostate Cancer and Metastatic Castration-resistant Prostate Cancer, this trial is actively recruiting participants. The trial is conducted by Janux Therapeutics and has accumulated 1 data snapshot since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Apr 23, 2026 – present · 49 days · daily APIRecruiting

Change History

1 version recorded
Recruiting [daily]

Eligibility Summary

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).

Contact Information

Sponsor contact:
  • Janux Therapeutics
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations